.40
  Price7.82%   +0.0290
(After Hours: .38 -0.0250 -6.25%)
Aug-04-22 05:54AM This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From YesterdayBenzinga
Aug-03-22 12:59PM Why Poseida Therapeutics Almost Doubled Today, Here Are 75 Stocks Moving In Wednesday's Mid-Day SessionBenzinga
07:50AM This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving PremarketBenzinga
Aug-03-22 06:07AM Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From YesterdayBenzinga
May-18-22 07:30AM Otonomy to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewswire Inc.
May-09-22 09:00AM Otonomy (OTIC) Q1 2022 Earnings Call TranscriptThe Motley Fool
04:04AM Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswire Inc.
May-02-22 07:30AM Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewswire Inc.
Apr-20-22 07:30AM Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing LossGlobeNewswire Inc.
Mar-15-22 07:30AM Otonomy to Host Virtual Investor R&D Event on March 22, 2022GlobeNewswire Inc.
Feb-28-22 09:00AM Otonomy (OTIC) Q4 2021 Earnings Call TranscriptThe Motley Fool
04:27AM Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswire Inc.
Feb-28-22 07:30AM Otonomy to Participate in Two Upcoming Investor ConferencesGlobeNewswire Inc.
Feb-25-22 07:30AM Otonomy to Host Virtual Investor R&D Event on March 22, 2022GlobeNewswire Inc.
Feb-24-22 08:01AM The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine CompanyBenzinga
Feb-22-22 07:30AM Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in TinnitusGlobeNewswire Inc.
Feb-20-22 08:06AM The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News FlowBenzinga
Feb-17-22 07:30AM Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate UpdateGlobeNewswire Inc.
Feb-16-22 07:30AM Otonomy Announces OTO-413 Presentations at American Auditory Society Annual MeetingGlobeNewswire Inc.
Otonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Cap:    |  Volume (24h):